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Objective: The purpose of this study was to determine the effect of sex on 30-day and long-term outcomes after elective
endovascular aneurysm repair.
Methods: Patients entered into the European collaborators on stent graft techniques for abdominal aortic aneurysm repair
(EUROSTAR) study formed the basis of our study. Data were analyzed by means of multivariable logistic regression for
30-day mortality and composite outcome of mortality, systemic complication, or conversion. Kaplan-Meier survival
analyses were used to compare long-term survival and long-term event-free survival times between women and men. The
log-rank test was used to test for differences. Cox proportional hazards regression was used to analyze survival and event-
free survival (with end point mortality or reintervention). Multivariable analyses were adjusted for age, comorbidities,
aneurysm characteristics, and treatment characteristics.
Results: There were 623 women and 8604 men available for analysis. No difference in 30-day mortality was demonstrated
for women compared with men (odds ratio, 0.89; 95% conﬁdence interval [CI], 0.48-1.67), but women did have
a signiﬁcantly higher cumulative incidence of the composite end point (odds ratio, 1.32; 95% CI, 1.05-1.66). The Kaplan-
Meier curves demonstrated worse outcomes for both long-term survival (P [ .05) and long-term event-free survival
(P[.005). Survival analyses adjusting for covariates demonstrated a higher albeit nonsigniﬁcant difference in long-term
mortality for women compared to men (hazard rate ratio, 1.21; 95% CI, 0.96-1.53) and a signiﬁcant higher rate of the
composite end point mortality or reintervention (hazard rate ratio, 1.28; 95% CI, 1.07-1.54).
Conclusions: Women undergoing endovascular aortic repair have higher complication and reintervention rates compared
with men, implying that the role of elective endovascular aneurysm repair in women needs to be examined more
closely. (J Vasc Surg 2013;58:42-9.)The three large randomized controlled trials comparing
endovascular aneurysm repair (EVAR) to open repair have
shown that 30-day mortality can signiﬁcantly be reduced
by endovascular repair.1-3 EVAR has been associated with
similar long-termmortality and higher delayed complication
and reintervention rates compared with open repair in the
EVAR 1 trial and Dutch Randomised Endovascular Aneu-
rysm Management (DREAM) trial but not in the Open
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Determining the role of EVAR for abdominal aortic
aneurysm (AAA) repair depends on being able to identify
variables that inﬂuence outcomes after EVAR. A recent
study demonstrated that age and the American Society of
Anesthesiology (ASA) Physical Status Classiﬁcation Score
are independent predictors of mortality. Sex was not an
independent predictor for mortality but was an indepen-
dent predictor for procedure-related complications,
women having a four times higher rate of complications
compared with men.4 It has been suggested, as is the
case for many other vascular procedures, that women
have more complications as a result of the smaller diameter
of their arteries. Various studies have put forward possible
mechanisms for the worse outcome and have demonstrated
signiﬁcantly higher mortality in women following (endo-
vascular) AAA repair.5-7 Such studies are few, and the
role of female sex has been poorly investigated mainly
because of the low proportion of females in clinical trials
evaluating EVAR.
The aim of this study, therefore, was to determine the
effect of sex on mortality and morbidity after endovascular
aneurysm repair using one of the largest endovascular
aneurysm repair registries.
Table I. Patient demographics
Women (623)
%/SD
Men (8604)
%/SD P valueAvailable Value Available Value
Age, years 623 (100%) 75 7.72 8604 (100%) 72 7.72 <.001
ASA (3 þ 4) 614 (98.6%) 316 51.47% 8501(98.8%) 4299 50.57% .668
Comorbidities (SVS)
Diabetes 597 (95.8%) 62 10.39% 8346 (97%) 1097 13.14% .053
Smoking 596 (95.7%) 182 30.54% 8316 (96.7%) 4312 51.85% <.001
Hypertension 598 (96%) 429 71.74% 8356 (97.1%) 5452 65.25% .001
Hyperlipidemia 585 (93.9%) 282 48.21% 8186 (95.1%) 3818 45.64% .464
Cardiac 595 (95.5%) 323 54.29% 8354 (97.1%) 5084 60.86% .002
Carotid 588 (94.4%) 95 16.16% 8254 (95.9%) 1455 17.63% .365
Renal 594 (95.3%) 94 15.82% 8282 (96.3%) 1605 19.38% .033
Pulmonary 593 (95.2%) 215 36.26% 8289 (96.3%) 3505 42.28% .004
Previous laparotomy 610 (97.9%) 217 35.57% 8472 (98.5%) 2148 25.35% <.001
Obesity 609 (97.8%) 170 27.91% 8461 (98.3%) 2233 26.39% .411
AAA characteristics (mean 6 SD)
AAA diameter 607 (97.4%) 57.34 11.04 8401 (97.6%) 58.16 12.29 .109
Neck diameter 600 (96.3%) 22.57 3.47 8234 (95.7%) 24.04 3.26 <.001
Neck length 589 (94.5%) 26.72 12.48 8046 (93.5%) 27.74 12.67 .059
Length lower a. renalis and iliac bifur 552 (88.6%) 116.17 20.18 7514 (87.3%) 119.06 20.63 .001
Signiﬁcant angulation 618 (99.2%) 366 59.22% 8559 (99.5%) 4312 50.38% <.001
Classiﬁcation of AAA 623 (100%) 73 11.71% 8604 (100%) 1600 18.59% <.001
Treatment characteristics
Time since start 623 (100%) 5.99 2.39 8604 (100%) 5.74 2.31 .007
Type of anesthesia
General 623 (100%) 444 71.27% 8604 (100% 5807 67.49% .052
Regional 623 (100%) 139 22.31% 8604 (100%) 2262 26.29% .029
Local 623 (100%) 40 6.42% 8604 (100%) 535 6.22% .840
AAA, Abdominal aortic aneurysm; ASA, American Society of Anesthesiology; SD, standard deviaiton; SVS, Society for Vascular Surgery.
Bold entries indicate statistical signiﬁcance.
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Study design. This study was part of the European
collaborators on stent graft techniques for abdominal aortic
aneurysm repair (EUROSTAR) study, a voluntary registry,
which was established in June 1996. The objective of the
EUROSTAR study was to collect and analyze information
from a prospective longitudinal cohort of patients who
underwent endovascular treatment of AAAs.8 Patients
with an asymptomatic intact and infrarenal aneurysm were
enrolled into the registry. The last patient was included in
November 2006. The median follow-up of the whole
cohort was 12.6 months.
Data collection. Patient characteristics, comorbidities,
aneurysm characteristics, treatment characteristics, postop-
erative outcomes, and information at follow-up visits (1, 3,
6, 12, 18, and 24 months, and yearly thereafter) were
recorded on a standardized case record form.8 All cardio-
vascular comorbidities were scored using the Society for
Vascular Surgery (SVS) e International Society for
Cardiovascular surgery risk score and recorded into a yes/
no variable where a score of 0 represented no comorbidity
present, and a score of 1, 2, or 3 indicated the comorbid-
ities present.9,10 The following commercially available and
CE-approved stent grafts were used: Zenith (Cook Inc,
Bloomington, Ind; 3705 patients), Talent (Medtronic
Vascular, Santa Rosa, Calif; 2589 patients), Excluder(W. L. Gore & Associates, Inc, Flagstaff, Ariz; 1290
patients), AneuRx (Medtronic Vascular; 1022 patients),
Powerlink (Endologix, Irvine, Calif; 166 patients), Lifepath
(Edwards Lifesciences, Irvine, Calif; 136 patients), Fortron
(Cordis, a Johnson & Johnson Company, Miami Lakes,
Fla; 97 patients), Anaconda (Sulzer Vascutek Ltd,
Inchinnan, Scotland; 87 patients), and EVT (Guidant Inc,
Menlo Park, Calif; 77 patients). In the remaining 58
patients, the type of stent graft used was not documented.
Patients treated with ﬁrst-generation devices (Vanguard or
Stentor stent graft; Boston Scientiﬁc Vascular, Natick,
Mass) were excluded from the analysis, as these devices
have long been withdrawn from the market.
Outcomes. The primary outcome was 30-day mor-
tality. Secondary outcomes were a 30-day composite end
point (consisting of mortality, systemic complications,
and conversion), long-term survival, and long-term event-
free survival. Thirty-day outcomes were included in the
analysis of long-term outcomes. Systemic complications
included cardiac, cerebral, pulmonary, renal, hepato-
bililiary, or bowel complications and sepsis. An event was
deﬁned as either death or a reintervention, which could be
a percutaneous transluminal angioplasty, a transabdominal
surgical intervention (conversion), or an extra-anatomic
surgical bypass procedure (femoral-femoral or axillo-
femoral crossover).
Table II. Thirty-day and long-term outcomes
Women (623) Men (8604)
P valueAvailable No./mean %/SD Available No./mean %/SD
Intraoperative
Duration of procedure, minutes 601 137.72 64.62 8303 128.99 58.42 .000
Replaced blood volume, mL 136 693.84 714.14 1289 583.18 737.79 .095
Endoleak 623 114 18.3 8604 1382 16.1 .144
Blocking of side branches 623 100 16.1 8604 1668 19.4 .041
Device-related complications 607 42 6.9 8502 351 4.1 .001
Failure to complete procedure 607 20 3.3 8502 122 1.4 .000
Arterial complications 607 34 5.6 8502 279 3.3 .002
From operation to discharge
Systemic complications 623 90 14.4 8604 927 10.8 .005
Procedure and device related 607 25 4.1 8502 216 2.5 .019
Access site and lower limb complications 607 56 9.2 8502 508 6.0 .001
Conversion to bifurcation graft 623 21 3.4 8604 179 2.1 .033
AAA rupture 623 2 0.3 8604 49 0.6 .581
Hospital stay 603 11.06 17.02 8412 7.62 10.15 .000
30-day death
All cause 623 12 1.9 8604 164 1.9 .972
Late outcomes
Abnormal ﬁndings or systemic complications 623 45 7.2 8604 649 7.5 .770
Procedure or device-related complications 623 144 23.1 8604 1868 21.7 .413
Graft migration 495 8 1.6 7272 133 1.8 .732
Graft stenosis 495 2 0.4 7272 51 0.7 .774
Graft thrombosis 495 7 1.4 7272 136 1.9 .465
Endoleak 495 55 11.1 7272 521 7.2 .001
AAA rupture 495 1 0.2 7272 35 0.5 .727
Intervention transfemoral (PTA) 495 25 5.1 7272 387 5.3 .794
Intervention transabdominal (conversion) 495 9 1.8 7272 88 1.2 .238
Intervention extra-anatomic (crossover) 495 7 1.4 7272 96 1.3 .860
Late death
All cause 623 72 11.6 8604 857 10 .201
AAA, Abdominal aortic aneurysm; PTA, percutaneous transluminal angioplasty; SD, standard deviaiton.
Bold entries indicate statistical signiﬁcance.
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27 variables were considered in the analyses and of the total
249,129 (that is, 9227  27) data points, 6286 (2.5%)
were missing values. We used multiple imputations
following fully conditional speciﬁcation to account for the
missing values and to avoid biased estimates of our
parameters.11
Data were presented for women and men separately.
Continuous variables were expressed as mean 6 standard
deviation, and categorical variables were presented as
frequencies. Differences in patient characteristics and
outcomes were compared with t-tests, Wilcoxon tests, or
the c2 statistic, as appropriate.
Multivariable logistic regression analysis was used to
compare 30-day outcomes between women and men
adjusting for covariates. Kaplan-Meier survival analysis
was used to compare long-term survival and long-term
event-free survival times between women and men without
adjustment. To test for differences, the log-rank test was
used. Cox proportional hazards regression analysis was
used to compare long-term outcomes between women
and men adjusting for covariates.
Odds ratios (ORs) for women compared with men were
calculated for the 30-day outcomes. Hazard rate ratios(HRRs) for women compared with men were calculated
for long-term outcomes. As the effect of sex was our main
interest, we constructed various models, starting with a uni-
variable model for sex and then gradually adding groups of
covariates to result in multivariable models to see whether
and how the outcome for sex was affected. The groups of
covariates we added were (1) age and ASA, (2) cardiovas-
cular risk factors or a history of cardiovascular disease or
other relevant disease (diabetes, smoking, hypertension,
hyperlipidemia, cardiac disease, carotid disease, pulmonary
disease, renal disease, previous laparotomy, and obesity),
(3) AAA characteristics (AAA diameter, neck diameter,
neck length, distance from the renal artery to iliac bifurca-
tion, signiﬁcant angulation, classiﬁcation of AAA into ﬁve
anatomic classes, representing increasingly complex
anatomy [class A with the least complex and class E as the
most complex anatomy according to the EUROSTAR
protocol8]), and ﬁnally, (4) treatment characteristics (time
since start of study indicating the degree of advancement
of the stent graft and type of anesthesia).
All tests were performed two-sided, and a probability
value of <.05 was considered statistically signiﬁcant. All
analyses were performed with SPSS software v. 17.0
(SPSS Inc, Chicago, Ill). The ﬁrst author (N.G.) had full
Table III. A, ORs from logistic regression analysis for 30-day mortality and for the combined end point of 30-day
mortality, systematic complications and conversion
30-day mortality
30-day mortality and systemic complications and
conversion
Univariable Multivariable Univariable Multivariable
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Sex 1.01 0.56-1.83 0.89 0.48-1.67 1.39 1.12-1.72 1.32 1.05-1.66
Age, years 1.07 1.05-1.10 1.02 1.01-1.03
ASA (3 or 4) 2.45 1.67-3.59 1.7 1.49-1.95
Cardiovascular comorbidities
Diabetes 1.05 0.68-1.64 0.94 0.77-1.13
Smoking 1.42 1.02-1.97 0.93 0.81-1.06
Hypertension 0.86 0.61-1.23 0.98 0.85-1.13
Hyperlipidemia 0.77 0.55-1.07 1.03 0.90-1.18
Cardiac 1.34 0.93-1.95 1.05 0.91-1.21
Carotid 1.22 0.83-1.77 1.03 0.87-1.21
Renal 2.02 1.43-2.82 1.41 1.21-1.65
Pulmonary 1.18 0.85-1.64 1 0.88-1.15
Previous laparotomy 1.04 0.74-1.47 0.98 0.85-1.13
Obesity 0.58 0.39-0.87 0.91 0.79-1.05
AAA characteristics
AAA diameter 1.03 1.02-1.04 1.01 1.01-1.02
Neck diameter 0.98 0.93-1.02 1.01 0.99-1.02
Neck length 0.99 0.97-1.00 0.99 0.99-1.00
Arteria renalis bifurcation 0.99 0.99-1.00 0.99 0.99-1.00
Signiﬁcant angulation 1.1 0.80-1.52 1.15 1.01-1.31
Classiﬁcation AAA 1.09 0.75-1.59 1.03 0.88-1.21
Treatment characteristics
Time since start 1.01 0.95-1.09 0.88 0.86-0.91
Type anesthesia 1.66 1.16-2.36 1.53 1.32-1.76
AAA, Abdominal aortic aneurysm; ASA, American Society of Anesthesiology; CI, conﬁdence interval; OR, odds ratio; SD, standard deviation.
Univariable is unadjusted; multivariable is adjusted for covariates. Bold entries indicate statistical signiﬁcance.
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responsibility for its integrity.RESULTS
There were 9227 patients for analysis (623 women and
8604 men). Mean age was 75 years for women and 72 years
for men (P < .001) (Table I). Regarding cardiovascular
comorbidities, women more often than men had hyperten-
sion and a previous laparotomy, whereas men more often
had diabetes, were current or ex-smokers, and had a history
of cardiac, renal, or pulmonary disease. For AAA character-
istics, women more often had signiﬁcant angulation of their
AAA and smaller neck diameters, whereas men more
frequently had unfavorably classed AAAs. Women more
often received general anesthesia, whereas men received
more regional anesthesia (Table I).
Thirty-day mortality was 1.9% for both women and
men, whereas intraoperative and postoperative (device
related and systemic) complications were signiﬁcantly
higher for women compared with men. Hospital stay was
also signiﬁcantly longer, on average 4 days, for women
than for men. Late outcomes did not differ signiﬁcantly
between women and men, except for the rate of endoleaks,
11.1% for women compared with 7.2% for men (P ¼ .001).Long-term mortality was 11.6% for women and 10% for
men (P ¼ .201) (Table II).
Multivariable logistic regression adjusting for age, ASA,
comorbidities, AAA characteristics, and treatment charac-
teristics demonstrated no difference in 30-day mortality
for women compared with men (OR, 0.89; 95% conﬁ-
dence interval [CI], 0.48 -1.67). Variables that did inde-
pendently inﬂuence 30-day outcome were age, ASA,
smoking, renal comorbidity, AAA diameter, and type of
anesthesia. General anesthesia was associated with a higher
mortality rate then regional or local anesthesia.
For the composite end point of 30-day mortality, sys-
temic complication, and conversion to a surgical procedure,
female sex did have an independent inﬂuence (OR, 1.32;
95% CI, 1.05-1.66). Other independent variables were
age, ASA, renal comorbidity, AAA diameter, signiﬁcant
angulation, time since start of the study, and type of anes-
thesia. (Table III, A).
The Kaplan-Meier survival curve and the log-rank test
(P ¼ .05) showed worse survival for women compared with
men (Fig 1). The Kaplan-Meier event-free survival curve
and the log-rank test (P ¼ .005) again showed worse
outcome for women compared with men (Fig 2). In the
Cox proportional hazards model adjusting for age, ASA,
cardiovascular comorbidities, AAA characteristics, and
Fig 1. Kaplan-Meier survival curves for women and men.
Fig 2. Kaplan-Meier event-free survival curves for women and men (death or reintervention).
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in survival for women compared with men (HRR, 1.21;
95% CI, 0.96-1.53). Variables that did inﬂuence survival
were age, ASA, smoking, hypertension, hyperlipidemia,
cardiac disease, renal disease, pulmonary disease, and
AAA diameter. For the composite end point of event-freesurvival (death or reintervention), female sex did have
a statistically signiﬁcant independent effect (HRR, 1.28;
95% CI, 1.07-1.54). Other independent variables were
age, ASA, hyperlipidemia, cardiac disease, renal disease,
pulmonary disease, AAA diameter, and type of anesthesia
(Table III, B).
Table III. B, HRRs from Cox proportional hazards regression analysis for survival and for event-free survival (death or
a percutaneous transluminal angioplasty, a transabdominal surgical intervention [conversion], or an extra-anatomic
surgical bypass procedure [femoral-femoral or axillo-femoral crossover])
Survival Event-free survival (death or reintervention)
Univariable Multivariable Univariable Multivariable
HRR 95% CI HRR 95% CI HRR 95% CI HRR 95% CI
Sex 1.25 1.00-1.56 1.21 0.96-1.53 1.30 1.09-1.56 1.28 1.07-1.54
Age, years 1.05 1.04-1.06 1.03 1.02-1.03
ASA (3 or 4) 1.63 1.42-1.87 1.28 1.15-1.43
Cardiovascular comorbidities
Diabetes 1.10 0.92-1.32 1.10 0.95-1.27
Smoking 1.14 1.01-1.30 1.02 0.92-1.13
Hypertension 0.84 0.74-0.96 0.97 0.87-1.08
Hyperlipidemia 0.71 0.62-0.82 0.79 0.70-0.88
Cardiac 1.23 1.07-1.42 1.15 1.03-1.29
Carotid 1.11 0.95-1.30 1.01 0.88-1.16
Renal 1.53 1.33-1.77 1.32 1.17-1.49
Pulmonary 1.32 1.16-1.50 1.23 1.11-1.36
Previous laparotomy 1.11 0.97-1.27 1.11 0.97-1.24
Obesity 0.88 0.76-1.02 0.92 0.82-1.03
AAA characteristics
AAA diameter 1.02 1.01-1.02 1.02 1.01-1.02
Neck diameter 1.02 1.00-1.04 1.02 1.00-1.04
Neck length 0.99 0.99-1.00 1.00 0.99-1.00
a. renalis bifurcation 1.00 1.00-1.01 1.00 1.00-1.00
Sign. angulation 0.95 0.84-1.08 1.00 0.91-1.11
Classiﬁcation AAA 1.12 0.97-1.30 1.19 1.05-1.35
Treatment characteristics
Time since start 0.98 0.95-1.01 0.97 0.94-0.99
Type anesthesia 1.13 0.98-1.29 1.15 1.03-1.29
AAA, Abdominal aortic aneurysm; ASA, American Society of Anesthesiology; CI, conﬁdence interval; HRR, hazard rate ratio.
Univariable is unadjusted; multivariable is adjusted for covariates. Bold entries indicate statistical signiﬁcance.
Table IV. Summary of primary and secondary outcomes for women compared with men
Univariate analysis Multivariate analysis
Mortality Composite end pointa Mortality Composite end pointa
30-day outcome (OR, 95% CI) NS 1.39 (1.12-1.72) NS 1.32 (1.05-1.66)
Survival Event-free survivalb Survival Event-free survivalb
Long-term outcome (HRR, 95% CI) NS 1.30 (1.09-1.56) NS 1.28 (1.07-1.54)
CI, Conﬁdence interval; HRR, hazard rate ratio; OR, odds ratio; NS, nonsigniﬁcant.
aComposite end point includes mortality, systemic complications, and conversion to open repair.
bEvent-free survival includes free of death or reintervention (transabdominal, percutaneous transluminal, or extra-anatomic repair).
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summarized in Table IV, where the ORs and HRRs for
women compared with men can be seen for both our
30-day and long-term outcomes.
DISCUSSION
The current study based on the EUROSTAR registry
represents one of the ﬁrst big-scale investigations into the
role of female sex on mortality and morbidity after EVAR.
No difference in 30-day mortality was demonstrated for
women compared with men, but women did have a higherincidence of the composite end point (mortality, systemic
complication, or conversion). Hospital stay was also longer
for women than for men. The Kaplan-Meier curves demon-
strated worse outcomes in women for both long-term
survival and long-term event-free survival. Adjusting for
covariates demonstrated a higher albeit statistically nonsig-
niﬁcant difference in long-term mortality and a statistically
signiﬁcant higher rate of the composite end point (mortality
or reintervention) in women compared with men.
Differences existed between women and men in the
registry, which need to be taken into account when
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were less favorable in women included their more advanced
age, more frequent hypertension or previous laparotomy,
less favorable AAA morphology, and more frequent use
of general anesthesia. To analyze whether these factors
can explain the poorer outcomes, we performed a multivari-
able adjustment and found that the OR and HRR for the
composite end points hardly decreased suggesting that
sex is an independent predictor for the composite end
point.
Anatomy is frequently indicated as an explanation for
the higher rate of complications (mostly periprocedural)
for women compared with men. This was conﬁrmed in
the present study in which anatomic differences between
men and women were observed. Because of women’s
smaller artery diameters, problems obtaining access and
completing the procedure can be expected more
frequently, as was demonstrated in this study (Table II).
Because of these difﬁculties, the procedural time was longer
in women than in men. Also, in women, signiﬁcantly more
frequent angulation of the aneurysm was observed
compared with men, which is another variable known to
negatively inﬂuence outcome.12
Our 30-day mortality outcomes are consistent with the
results from three randomized controlled trials of endovas-
cular AAA repair demonstrating no difference between
women and men.1-3 An inferior 30-day composite end
point for women compared with men, however, has not
previously been demonstrated to such an extent.
The EVAR-1 trial depicted a trend of worse outcomes
for serious graft complications after EVAR (HRR, 1.46;
95% CI, 0.91-2.36) and reinterventions after EVAR
(HRR, 1.60; 95%CI, 0.98-2.88) for women but was unable
to demonstrate a signiﬁcant difference probably because of
the small sample size of women (n ¼ 79). In contrast, our
study included a far larger number of women, and clearly
demonstrated a signiﬁcant difference in the composite 30-
day (death, systemic complications, or conversion) and
composite long-term end point (death or reintervention).
Inferior outcomes in both early and long-term
composite end points may have a common cause, in that
complications and reinterventions are less well tolerated
by women. Reinterventions may technically be more
complicated because of smaller access vessels and in case
of open procedures because of a higher incidence of
previous laparotomies. Worse outcomes in women have
been attributed in part to a late diagnosis. However, the
intensity of follow-up surveillance in women and men
was not different in the EUROSTAR cohort.13
Wisniowski et al recently also demonstrated female sex
to be an independent predictor of higher reintervention
rates compared with men with only 15 women in his
study.4 With respect to the other variables, which were
independently associated with worse outcome, our study
demonstrated that high ASA class, renal comorbidity,
type of anesthesia, and age are the major variables that
have a negative impact on outcome, which is in line with
most other large studies.14This study has several limitations. First, this study was
based on registry data collected in daily clinical practice. As
with all registries, inclusion of all consecutive patients at all
sites cannot be ensured, leading to possible generalizability
issues. Nevertheless, everything was done to make the
registry as complete as possible. Second, it is possible that
eventswere not recorded because of loss of follow-up. Third,
no comprehensive information regarding medication was
documented in the database, making it impossible to adjust
for its effect. A particularly disturbing issue was that many
diameter data of the iliac arteries were missing, precluding
assessment of their inﬂuence on early and late outcome
events. This omission was due to the practical consequences
of a voluntary database in which participants sometimes did
not complete all requested data. Smaller access vessels in
womenmay be associatedwith a higher risk of intraoperative
mishaps (ie, inability to introduce the endograft) and in the
early or late postoperative period with graft-limb occlusion.
Finally, although we demonstrated a correlation between
sex and outcome, a true causal relationship is difﬁcult if not
impossible to establish. It is difﬁcult to convincingly demon-
strate whether the poorer outcome was due to female sex as
such or to factors of adverse anatomy. We think that the
cause is multifactorial. All in all, there is an independent
correlation of female sex with the poorer early and late
outcome, however, the cause is not really known. Findings
in the present and other studies suggest that women need
to be treated by smaller-caliber introducer systems and
more ﬂexible devices than men. Since our patients were
enrolled into the registry, the device industry had made
considerable progress to improve aortic endografts in that
respect. However, studies demonstrating comparable
outcomes in both sexes are still lacking. Modeling and
cost-effectiveness studies are needed to assess the impact of
newer devices on higher complications rates, longer hospital
stays, and poorer outcomes of reinterventions in women.
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The EUROSTAR Collaborative Centers are as
follows:
Austria: Vienna, University Hospital.
Belgium: Aalst, City Hospital; Aalst, Onze Lieve
Vrouwe Hospital; Antwerpen, Hospital Middelheim; Ant-
werpen, St Vincentius Hospital; Antwerpen, University
Hospital; Antwerpen, Monica Hospital/OLV/Eeuwfeest-
kliniek; Antwerpen, St Augustinus Hospital; Arlon, Clini-
que St Joseph; Assebroek, Hospital St Lucas/St Jozef;
Aye, Hospital Princesse Paola; Baudour, Reseau Hospital
de Medecine Sociale; Bonheiden, Imelda Hospital; Bras-
schaat, Hospital Klina; Brugge, Hospital St Jan; Brussels,
Hospital Erasme; Brussels, Free University Hospital; Brus-
sels, Clinique de l’Europe St Michel; Brussels, Hospital
Brugmann; Brussels, Central Hospital Edith Cavell; Brus-
sels, Hospital d’Iris Sud; Brussels, University Hospital St
Luc; Brussels, Clinique Saint Jean; Charleroi, University
Hospital; Dendermonde, Hospital St Blasius; Duffel,
Hospital St Maarten; Eeklo, Hospital Heilig Hart; Geel,
Hospital St Dimpna; Genk, St Jan Hospital; Gent, Volks-
kliniek; Gent, Hospital St Lucas; Gent, St Jan Palﬁjn
Hospital; Gent, University Hospital; Gent, Hospital Maria
Middelares - St Jozef; Gilly, St Joseph Hospital; Haint
Saint Paul, Hospital de Jolimont; Halle, Hospital St Maria;
Hasselt, Virga Jesse Hospital; Herenthals, St Elisabeth
Hospital; Heusden-Zolder, St Franciskus Hospital; Ieper,
Hospital Jan Yperman; Knokke, Gezondheidszorg Oost-
kust; Kortrijk, Hospital Groenige; La Louvie` re, Central
Hospital de Tivoli; Leuven, University Hospital; Leuven,
Heilig Hart; Lie` ge, University Hospital; Lie` ge, Hospital
St Joseph; Lie`ge-Chenee, Notre Dame des Bruyeres; Lier,
Heilig Hart Hospital; Lommel, Maria Hospital; Malmedy,
Hospital Reine Astrid; Mechelen, Onze Lieve Vrouwe
Hospital; Mont Godinne, Hospital de Mont Godinne;
Mouscron, Central Hospital; Namur, Central Hospital
Regional; Namur, Hospital St Elisabeth; Ottignies, Clini-
que Saint-Pierre; Reet, Hospital Heilige Familie; Roeselare,
City Hospital; Roeselare, Heilig Hart Hospital; Sambre-
ville, Hospital Val de Sambre; St Niklaas, Hospital Maria
Middelares; St Truiden, St Trudo Hospital; Tielt, St
Andries Hospital; Tongeren, Hospital Vesalius; Tournai,
Hospital Notre Dame et St Georges; Tournai, Central
Hospital; Turnhout, St Josef Hospital; Turnhout, St Elisa-
beth Hospital; Veurne, St Augustinus Hospital; Vilvoorde,
St Josef Hospital; Zottegem, St Elisabeth Hospital.
Denmark: Copenhagen, Rigshospitalet; Odense,
University Hospital.
France: Draguignan, Hospital Notre Dame; Lyon,
Hospital E Herriot; Paris, Hospital Henri Mondor.
Germany: Bonn, Surgical University Hospital; Dussel-
dorf, Augusta Hospital; Frankfurt, City Hospital; Frank-
furt, Bethanien Hospital; Frankfurt, St Katharinen
Hospital; Hamburg, Altona General Hospital; Karlsruhe,
Hospital Karlsruhe; Kempten, Hospital Kempten;
Koblenz, Bundeswehrzentral; Leipzig, Park-Hospital;Marburg, Philipps-University; Munchen, Hospital Rechts
der Isar; Munchen, City Hospital; Mü nchen, Ludwig-
Maximilian University Hospital; Oldenburg, Pius Hospital;
Ulm, University Hospital.
Greece: Athens, University Medical School.
Ireland: Dublin, St James Hospital.
Israel: Tel Aviv, Sheba Medical Centre.
Italy: Perugia, Hospital Monteluce; Roma, Hospital
San Giovanni; Varese, Hospital diCircolo.
Luxembourg: Luxembourg, Central Hospital.
Monaco: Monaco, Cardiothoracic Centre.
The Netherlands: Alkmaar, Medical Centre; Amster-
dam, Academic Medical Centre; Amsterdam, Free Univer-
sity Hospital; Amsterdam, Onze Lieve Vrouwe Hospital;
Apeldoorn, Gelre Hospital; Arnhem, Rijnstate; Breda,
Amphia Hospital; Delft, Reinier de Graaf Group; Doetin-
chem, Slingerland Hospital; Dordrecht, Albert Schweitzer
Hospital; Drachten, Ny Smellinghe Hospital; Eindhoven,
Catharina Hospital; Enschede, Medisch Spectrum Twente;
Geldrop, St Anna Hospital; Groningen; University
Hospital; Groningen, Martini Hospital; Leeuwarden,
Medical Centre; Maastricht, University Hospital; Nieuwe-
gein, St Antonius Hospital; Nijmegen, Canisius Wilhelmina
Hospital; Nijmegen, University Hospital St Radboud; Rot-
terdam, St Clara Hospital; Rotterdam, Dijkzicht Hospital;
Rotterdam, Franciscus Hospital; The Hague, Medical
Centre Haaglanden Westeinde; The Hague, Leijenburg
Hospital; Tilburg, Elisabeth Hospital; Tilburg, Tweesteden
Hospital; Utrecht, University Hospital; Veldhoven, St
Josef Hospital; Zwolle, Isala Hospital
Norway: Oslo, Aker University Hospital; Oslo, Ulleval
Hospital; Trondheim, University Hospital.
Poland: Lublin, L’Academie de medicine; Warsaw,
Medical University; Warsaw, MSWiA Hospital; Warsaw,
Central Military Hospital.
Spain: Barcelona, University Hospital; Barcelona, Ciu-
tat Sanitaria I Universitaria de Bellvitge; Barcelona,
Hospital Santa Creu I S Pau; Donostia San Sebastian,
Hospital de Gipuzkoa; La Corunea, Hospital Juan Canal-
ejo; La Corune a, Hospital Santa Teresa; Leon, Hospital
de Leon; Lugo, Hospital Xeral Lugo; Madrid, University
Hospital de la Princesa; Madrid, Virgen de la Salud;
Madrid, Hospital Ramon y Cajal; Madrid, Fundacion Jime-
nez Diaz; Madrid, University Hospital of Getafe; Madrid,
Hospital de la Zarzuele; Madrid, Hospital Ruber Interna-
tional; Malaga, HR Carlos Haya; Pamplona, University
Hospital of Navarra; Valladolid, Hospital Valladolid.
Sweden: Lund, University Hospital; Orebro, Medical
Centre; Stockholm, Karolinska Hospital.
Switzerland: Bern, Clinic for Cardiovascular Surgery;
Zurich, Gefasszentrum.
Turkey: Ankara, Hacettepe University Hospital; Istan-
bul, Memorial Hospital; Istanbul, University Hospital.
UnitedKingdom:Bournemouth, RoyalHospital; Bris-
tol, Royal Inﬁrmary; Chester, Countess of ChesterHospital;
Glasgow, Gartnavel Hospital; Hull, Royal Inﬁrmary; Liver-
pool, Royal University Hospital; Manchester, Withington
Hospital; New Castle-Upon-Tyne, Freeman Hospital.
